In July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted against recommending BPC-157, TB-500, KPV, and MOTS-c for the 503A bulk drug substances list. The committee cited absent human pharmacokinetic data, unresolved oncological signals for the angiogenic peptides, and no approved human indication for any of the four compounds as the primary evidentiary basis for each negative vote.
What Is the PCAC and How Does Its July 2026 Vote Affect Compounding Access?
The Pharmacy Compounding Advisory Committee evaluates bulk drug substances nominated for the 503A and 503B compounding lists under the Drug Quality and Security Act of 2013. A negative PCAC recommendation signals the FDA's intent to exclude a substance from the bulk list, effectively ending legal compounding pathways for most practitioners and pharmacies without prohibiting possession outright.
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound from a bulk substance only if that substance appears on an FDA-approved list, the preparation is not essentially a copy of a commercially available product, and other statutory conditions are met. The 503B pathway applies to outsourcing facilities and carries stricter manufacturing requirements. Neither pathway is available for substances the FDA has declined to add to the bulk list.
The DQSA framework requires the FDA to evaluate nominated substances against three criteria: clinical need, safety of compounding, and patient risk. The July 2026 PCAC votes on all four peptides turned primarily on the second and third criteria — safety and risk — rather than on clinical need, which proponents argued was substantial.
The practical consequence of a negative PCAC recommendation is that 503A compounding pharmacies cannot legally prepare these peptides from bulk drug substances for patient-specific prescriptions. Practitioners who have been sourcing compounded versions of these peptides face a narrowing legal corridor that the July 2026 votes made materially tighter.
What Safety Data Drove the PCAC Vote Against Compounding BPC-157?
The PCAC's negative vote on BPC-157 rested on three documented concerns: no completed human pharmacokinetic or pharmacodynamic study, a credible oncological risk signal from the peptide's VEGFR2-mediated pro-angiogenic activity, and immunogenicity risks from non-GMP manufacturing of injectable preparations. No IND-supported Phase I safety trial in humans had been completed at the time of the vote.
BPC-157 is a 15-amino-acid synthetic pentadecapeptide derived from a sequence in human gastric juice protein. Its preclinical regenerative profile is well-documented across rodent models of tendon, muscle, bone, and nerve injury — with reproducible effects attributed to VEGFR2 upregulation, FAK–paxillin fibroblast activation, and nitric oxide pathway modulation. The McGuire 2025 narrative review in Current Reviews in Musculoskeletal Medicine (18:611–619) characterised this evidence base as "biologically compelling but clinically immature."
The oncological concern is mechanistic rather than observational: VEGFR2 is the primary receptor through which VEGF drives tumour angiogenesis, and any compound that potently upregulates this pathway warrants formal oncological safety evaluation before widespread clinical use. The PCAC noted that no study had specifically examined BPC-157 administration in patients with active or occult malignancy, and that anti-apoptotic signalling documented in preclinical models created a secondary theoretical risk for malignant cell survival.
WADA added BPC-157 to its Prohibited List effective January 2025, classifying it under peptide hormones, growth factors, and related substances. The FDA's position that compounded BPC-157 presents significant safety risks predates the July 2026 vote and was reinforced by the committee's review of the accumulated preclinical oncology literature.
Why Did the PCAC Vote Against TB-500, and What Oncological Evidence Was Central?
The PCAC vote against TB-500 — the synthetic 17-amino-acid thymosin beta-4 fragment spanning residues 17–23 — was driven by the same pro-angiogenic oncological concern as BPC-157, compounded by complete absence of controlled human exposure data. The FDA had placed TB-500 on its Category 2 list in 2023; the July 2026 vote confirmed no new human safety data had emerged.
Thymosin beta-4 (Tβ4) upregulates VEGF through HIF-1α stabilisation, a mechanism that operates independently of hypoxia. Because VEGF is the primary driver of the angiogenic switch that converts dormant tumour cell clusters into vascularised, actively growing lesions, this constitutes a biologically credible pathway to dormant tumour reactivation. The PCAC acknowledged that the mechanistic chain from exogenous TB-500 to VEGF upregulation has not been directly tested — but noted the absence of exculpatory data carries equal weight.
Multiple independent preclinical studies document Tβ4 overexpression correlating with tumour progression. In pancreatic cancer cell lines, elevated Tβ4 stimulated proinflammatory cytokine secretion and activated JNK signalling (PMC2930015). In colorectal cancer models, Tβ4 drove invasion and migration via the ILK/AKT/β-catenin pathway. These findings concern endogenous overexpression rather than exogenous administration — a distinction the PCAC acknowledged while noting the mechanistic overlap cannot be dismissed.
The literature contains contradictory signals: decreased Tβ4 expression correlates with worse prognosis in multiple myeloma, and a 2023 MDPI study found exogenous recombinant Tβ4 suppressed lung cancer progression in an IPF-associated mouse model. The PCAC's position was not that TB-500 is proven to cause cancer, but that oncological uncertainty — absent human safety data — is sufficient to preclude a positive compounding recommendation.
What Evidence Did the PCAC Review for KPV, and Why Was the Vote Negative?
KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-MSH with documented anti-inflammatory activity in preclinical models of inflammatory bowel disease and skin inflammation. The PCAC's negative vote reflected a different evidence profile than BPC-157 or TB-500: the primary concern was absent human pharmacokinetic data for injectable KPV and the lack of any approved indication to anchor a compounding risk-benefit assessment.
KPV exerts anti-inflammatory effects primarily through melanocortin receptor 1 (MC1R) binding and downstream NF-κB suppression, reducing production of TNF-α, IL-6, and IL-1β. Preclinical data in murine colitis models show significant reductions in inflammatory markers with oral and intracolonic KPV administration. A 2022 study demonstrated that KPV-loaded nanoparticles achieved targeted colonic delivery with reduced systemic exposure — a finding relevant to safety but not yet replicated in human trials.
The PCAC noted that KPV's tripeptide structure makes it substantially more stable than larger peptides and less likely to generate immunogenic responses — a point proponents used to argue for a more permissive compounding stance. The committee's response was that stability and low immunogenicity reduce one risk category but do not substitute for human pharmacokinetic data or an approved clinical indication. The absence of any IND-supported human trial for injectable KPV was the decisive evidentiary gap.
The PCAC's briefing materials distinguished between oral and injectable KPV routes, with the injectable form carrying higher risk due to systemic exposure and absent bioavailability data in humans. Oral KPV formulations for inflammatory bowel disease represent the most clinically developed application, and the negative vote applies specifically to compounded injectable preparations.
What Is MOTS-c and What Safety Concerns Drove the PCAC's Negative Recommendation?
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene — one of the few peptides of mitochondrial DNA origin. It regulates metabolic homeostasis through AMPK activation. The PCAC's negative vote reflected the earliest-stage evidence profile of the four compounds: no completed human trials, no established human pharmacokinetic profile, and no regulatory precedent for compounding a mitochondrially-encoded peptide.
MOTS-c activates AMPK by translocating to the nucleus under metabolic stress, where it regulates the AMPK–SIRT1–PGC-1α axis governing mitochondrial biogenesis and fatty acid oxidation. In aged mouse models, exogenous MOTS-c administration improved insulin sensitivity, reduced adiposity, and extended median lifespan — findings that have generated substantial research interest but remain entirely preclinical. No Phase I safety or pharmacokinetic study in humans had been registered or completed at the time of the July 2026 vote.
The PCAC's specific safety concerns for MOTS-c centred on three unknowns: the immunogenic potential of a mitochondrially-encoded peptide administered exogenously, the absence of GLP-compliant animal toxicology data, and the theoretical risk of disrupting endogenous mitochondrial signalling networks through supraphysiological exogenous dosing. These concerns are distinct from the oncological signals that dominated the BPC-157 and TB-500 reviews.
MOTS-c's mitochondrial origin creates a unique regulatory consideration: its endogenous expression is tightly coupled to mitochondrial respiratory status, and the consequences of decoupling this regulation through exogenous administration have not been characterised. The PCAC flagged this as a first-principles safety question that GLP-compliant preclinical toxicology studies — not yet conducted — would need to address before any compounding pathway could be considered.
What Safety Themes Were Common Across All Four PCAC Votes?
Three safety themes recurred across all four negative votes: absent human pharmacokinetic data, immunogenicity and endotoxin contamination risks from non-GMP bulk drug substances in injectable preparations, and the lack of any approved clinical indication to anchor a risk-benefit assessment. These structural evidentiary gaps — not compound-specific toxicity findings — formed the common basis for the committee's recommendations.
The immunogenicity concern for compounded injectable peptides is not theoretical. Non-GMP synthesis introduces sequence errors, truncated fragments, and oxidised residues that can act as neoantigens. The FDA's 2023 Category 2 designations for multiple peptides explicitly cited immunogenic potential from impure preparations as a patient safety risk. Compounding pharmacies operating under 503A are not required to meet the same sterility and purity standards as licensed drug manufacturers.
Endotoxin contamination from bacterial synthesis processes represents a separate serious risk for injectable peptides. Lipopolysaccharide contamination at levels below the detection threshold of standard limulus amebocyte lysate testing can trigger systemic inflammatory responses in susceptible patients. The PCAC noted that no compounding pharmacy-level testing protocol reliably excludes sub-threshold endotoxin contamination from peptide injectables.
The committee also addressed the political context of the July 2026 review: public advocacy had generated pressure for the FDA to ease peptide compounding restrictions. The PCAC's role is advisory and evidence-based; its negative votes reflected the evidentiary record. The committee explicitly noted that clinical need arguments — however compelling — cannot substitute for safety data in the DQSA evaluation framework.
What Does the Regulatory Status of Each Compound Mean for Practitioners in 2026?
Following the July 2026 PCAC votes, none of the four compounds has a legal compounding pathway under 503A bulk drug substance provisions in the United States. Practitioners face a clear informed-consent obligation: patients must be advised of unapproved status, the specific PCAC safety concerns, manufacturing quality risks, and the absence of human pharmacokinetic data.
| Compound | FDA Category (Pre-July 2026) | PCAC July 2026 Vote | Primary Safety Concern Cited | Human Clinical Trial Status |
|---|---|---|---|---|
| BPC-157 | Category 2 (significant safety risk) | Negative — do not add to 503A list | VEGFR2-mediated oncological risk; no human PK/PD data; immunogenicity | No completed Phase I; one registered RCT (NCT07437547) unpublished |
| TB-500 (Tβ4 fragment) | Category 2 (significant safety risk) | Negative — do not add to 503A list | HIF-1α/VEGF angiogenic switch risk; absent human exposure data | No completed or registered human trial |
| KPV (Lys-Pro-Val) | Not previously categorised for injectable route | Negative — injectable form not recommended | Absent injectable PK data; no approved indication for compounding anchor | No completed human injectable trial; oral IBD research ongoing |
| MOTS-c | Not previously categorised | Negative — do not add to 503A list | Novel mitochondrial origin; absent GLP toxicology; no human PK data | No completed or registered human trial |
Safety Considerations for Practitioners: Informed Consent After the July 2026 PCAC Votes
The July 2026 PCAC votes create a heightened informed-consent standard for practitioners discussing these four peptides with patients. The committee's formal negative recommendations constitute a documented regulatory record that must be addressed explicitly — covering unapproved status, compound-specific safety concerns, manufacturing quality risks, and the absence of human pharmacokinetic data.
For BPC-157 and TB-500 specifically, practitioners should formally document that patients with a personal or family history of cancer, or with known subclinical lesions, face a theoretically elevated risk profile from pro-angiogenic peptide administration. The oncological concern is mechanistically grounded in peer-reviewed literature and has been acknowledged by the PCAC. This is an unresolved risk — not a speculative one — which is a materially different evidentiary status.
For KPV, the informed-consent discussion should distinguish between oral and injectable routes. The PCAC's concerns focused on injectable preparations; the oral anti-inflammatory application in IBD contexts carries a different risk profile, though it also lacks regulatory approval. Practitioners using oral KPV formulations should document this route distinction and the absence of any approved indication.
For MOTS-c, the complete absence of human data — including the absence of any GLP-compliant toxicology study — means practitioners are operating in a genuine epistemic void. The appropriate informed-consent framing is that MOTS-c is at the earliest stage of the research pipeline, that no safety floor has been established in humans, and that the July 2026 PCAC vote reflects this fundamental data gap rather than a specific identified harm.
For cross-compound context on the mechanistic oncology signals that informed the BPC-157 and TB-500 votes, see What Does 2026 Research Show About BPC-157 for Musculoskeletal Healing — Regeneration or Risk? on Peptide Therapy Index. For the metabolic and AMPK context behind MOTS-c's research profile, see How Does MOTS-c Activate AMPK and What Does That Mean for Metabolic Performance in 2026? on Peptidegenics. Which Peptides Could Exit the FDA's Compounding Restriction List After the July 2026 Advisory Vote? Why Did FDA Scientists Recommend Against Adding TB-500, BPC-157, and MOTS-C to the Compounding Greenlist in July 2026? What Did the July 2026 FDA PCAC Review Conclude About BPC-157's Biopharmaceutical Data Gaps and 503A Compounding Eligibility?